Literature DB >> 12856155

Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.

Markus Luster1, Steven I Sherman, Monica C Skarulis, James R Reynolds, Michael Lassmann, Heribert Hänscheid, Christoph Reiners.   

Abstract

Iodine kinetics were studied in patients with differentiated thyroid cancer while euthyroid under exogenous thyroid stimulating hormone (TSH) and while hypothyroid to detect differences in radioiodine uptake, distribution and elimination. Nine patients with total or near-total thyroidectomy on thyroid hormone suppressive therapy received two or three daily doses of 0.9 mg recombinant human TSH (rhTSH) followed by administration of a diagnostic activity of 2 mCi (74 MBq) iodine-131. After the biokinetics assessments had been performed, patients stopped taking thyroid hormones to become hypothyroid. A second 2 mCi (74 MBq) diagnostic activity of 131I was administered, followed by a second set of biokinetics assessments. One week later the patients underwent remnant ablation with a therapeutic activity of 131I. A comparison of the 131I kinetics in the patients while euthyroid and while hypothyroid showed major differences in the doses to the remnant as well as in residence times and radiation exposure to the blood. In the first diagnostic assessment the remnant dose was higher in eight of the nine patients and clearance of the activity from the blood was faster in all of them. The data from this study suggest that radioiodine administration is potent and safe when administered to euthyroid patients following rhTSH administration. Enhanced residence time in the remnant and decreased radiation exposure to the blood were noted when patients were euthyroid compared to when they were rendered hypothyroid. However, all patients received diagnostic activities in the same order: first while euthyroid, followed by hypothyroidism. It is quite possible that "stunning" from the radioiodine administered in the initial uptake study inhibited the subsequent uptake of radioiodine by the remnant lesions in the second uptake study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12856155     DOI: 10.1007/s00259-003-1230-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours.

Authors:  Stephen K Gerard; Ralph R Cavalieri
Journal:  Clin Nucl Med       Date:  2002-01       Impact factor: 7.794

Review 2.  Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer.

Authors:  H R Maxon; H S Smith
Journal:  Endocrinol Metab Clin North Am       Date:  1990-09       Impact factor: 4.741

3.  Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.

Authors:  C Bal; A K Padhy; S Jana; G S Pant; A K Basu
Journal:  Cancer       Date:  1996-06-15       Impact factor: 6.860

4.  74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer.

Authors:  I R McDougall
Journal:  Nucl Med Commun       Date:  1997-06       Impact factor: 1.690

5.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.

Authors:  P W Ladenson; L E Braverman; E L Mazzaferri; F Brucker-Davis; D S Cooper; J R Garber; F E Wondisford; T F Davies; L J DeGroot; G H Daniels; D S Ross; B D Weintraub
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

6.  Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.

Authors:  S J Mandel; L K Shankar; F Benard; A Yamamoto; A Alavi
Journal:  Clin Nucl Med       Date:  2001-01       Impact factor: 7.794

7.  Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells.

Authors:  T Kogai; T Endo; T Saito; A Miyazaki; A Kawaguchi; T Onaya
Journal:  Endocrinology       Date:  1997-06       Impact factor: 4.736

8.  Absorbed dose calculations to blood and blood vessels for internally deposited radionuclides.

Authors:  G Akabani; J W Poston
Journal:  J Nucl Med       Date:  1991-05       Impact factor: 10.057

9.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

10.  Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer.

Authors:  S R Thomas; R C Samaratunga; M Sperling; H R Maxon
Journal:  Nucl Med Biol       Date:  1993-02       Impact factor: 2.408

View more
  30 in total

Review 1.  ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?

Authors:  Daniele Barbaro; Frederik A Verburg; Markus Luster; Christoph Reiners; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

2.  Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Thyroid       Date:  2012-02-07       Impact factor: 6.568

3.  Decreased radioiodine uptake of FRTL-5 cells after (131)I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway.

Authors:  Birgit Meller; Erzsébet Gaspar; Wibke Deisting; Barbara Czarnocka; Manfred Baehre; Björn E Wenzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-29       Impact factor: 9.236

4.  What role for recombinant human TSH in the treatment of metastatic thyroid cancer?

Authors:  Paolo Zanotti-Fregonara; Elif Hindié; Marie Elisabeth Toubert; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06       Impact factor: 9.236

Review 5.  The role of nuclear medicine in differentiated thyroid cancer.

Authors:  Susanne Kohlfürst
Journal:  Wien Med Wochenschr       Date:  2012-07-20

6.  A placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer.

Authors:  Birte Nygaard; Lars Bastholt; Finn Noe Bennedbæk; Tobias Wirenfeldt Klausen; Jens Bentzen
Journal:  Eur Thyroid J       Date:  2013-09-07

7.  The relationship between expression of the sodium/iodide symporter gene and the status of hormonal receptors in human breast cancer tissue.

Authors:  Hyun Jung Oh; June-Key Chung; Joo Hyun Kang; Won Jun Kang; Dong Young Noh; In Ae Park; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

8.  Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen.

Authors:  I Borget; H Remy; J Chevalier; M Ricard; M Allyn; M Schlumberger; G De Pouvourville
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-02       Impact factor: 9.236

9.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

10.  Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium.

Authors:  Daniele Barbaro; Mariano Grosso; Giuseppe Boni; Paola Lapi; Cristina Pasquini; Paola Orsini; Anna Turco; Giuseppe Meucci; Maria Cristina Marzola; Piero Berti; Paolo Miccoli; Giuliano Mariani; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.